This hasn’t been a great market for so-called quality stocks, typically defined as blue chips with steady profits and low debt. That makes it all the more impressive that funds run by GMO’s Tom ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Eli Lilly and Co. is planning to build a new $6 billion manufacturing facility in Huntsville, Alabama. (Rendering courtesy of Eli Lilly and Co.) Eli Lilly and Co. on Tuesday announced plans to spend ...

Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ...

Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY) posted 54% revenue growth driven by ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...